Scancell CEO hails "exciting" high response rate to melanoma treatment - Professor Lindy Durrant (Chief Executive Officer, Chief Scientific Officer), Scancell Holdings 00:00:00
Lindy is an internationally recognised immunologist in the field of tumour therapy and co-founder of Scancell. She has worked for over 25 years in translational research, developing products for clinical trials including monoclonal antibodies and cancer vaccines. She has a personal Chair in Cancer Immunotherapy in the Department of Clinical Oncology at the University of Nottingham.
